ADVITOS
Munich
About ADVITOS
ADVOS is the world’s first method for the combined multi-organ support of liver, lung, kidney, and acid-base balance. Based on the principle of albumin dialysis, ADVOS allows extracorporeal fluid-based elimination of CO2, hepatic toxins, water-soluble and protein-bound nephrotoxins, as well as the correction of metabolic and respiratory acidosis. The ADVOS method works with typical dialysis accesses and flow rates and does not require any gas exchangers for CO2 elimination.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $25.4M
- Last round: Series Unknown (Jun 2021)
- Website: advitos.com
- Phone: +49 89 411 18 42 00
Industries & Categories
Medical, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/advitos-148428 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.